Biosimilars

Biosimilars are a rapidly growing treatment option for physicians treating advanced diseases, with more than 20 unique biosimilars expected to enter the U.S. healthcare market over the next decade. Learn more about these safe and effective treatment options.

Read below for biosimilar resources at every stage: biosimilar beginners, considerations when using biosimilars, and best practices post-adoption.

New to biosimilars?

  • Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing, FDA-approved reference biologics.
  • While biosimilars are similar to their reference biological product, they are not generic equivalents.
  • Biosimilars go through a rigorous FDA review process including analytical, animal and clinical studies.

Biosimilars go through an extensive FDA approval process and offer safe, effective therapeutic options for serious diseases

As more biosimilars become available in the U.S., providers, payers and patients all stand to benefit from further incorporating these safe and effective therapies throughout our healthcare ecosystem.

Rising healthcare costs, increasing drug production demands and reimbursement pressures are all putting a serious strain on our nation鈥檚 healthcare delivery system. By adopting biosimilars routinely into patient treatment decisions, we can improve overall access to critical, life-saving drugs all while reducing the costs of these expensive therapies through increased competition.

Learn more about the McKesson services available to support biosimilar and other practice needs by visiting our Solutions for Specialty Practices page.

Considering adopting biosimilars in your treatment regimens?

Biosimilars Currently Available through McKesson Include:

Biosimilar Drug

Biologic Reference Drug

HCPCS Code聽

Patient Support Services

Full Prescribing Information

Mvasi
(bevacizumab-awwb)

Avastin

Q5107

(PDF, 627 KB)

Zirabev
(bevacizumab-bvzr)

Avastin

Q5118

(PDF, 1 MB)

Retacrit
(epoetin alfa-epbx)

Epogen/Procrit

Q5105 (ESRD use)
Q5106 (non-ESRD use)

(PDF, 614 KB)

Herzuma
(trastuzumab-pkrb)

Herceptin

Q5113

(PDF, 551 KB)

Kanjinti
(trastuzumab-anns)

Herceptin

Q5117

(PDF, 834 KB)

Ogiviri
(trastuzumab-dkst)

Herceptin

Q5114

Ontruzant
(trastuzumab-dttb)

Herceptin

Q5112

Trazimera
(trastuzumab-qyyp)

Herceptin

Q5116

(PDF, 706 KB)

Fulphila
(pegfilgrastim-jmdb)

Neulasta

Q5108

(PDF, 921 KB)

Udenyca
(pegfilgrastim-cbqv)

Neulasta

Q5111

(PDF, 1 MB)

Ziextenzo
(pegfilgrastim-bmez)

Neulasta

Q5120

Nivestym
(filgrastim-aafi)

Neupogen

Q5110

(PDF, 921 KB)

Zarxio
(filgrastim-sndz)

Neupogen

Q5101

(PDF, 3 MB)

Avsola
(infliximab-axxq)

Remicade

Q5121

Inflectra
(infliximab-dyyb)

Remicade

Q5103

(PDF, 1 MB)

Renflexis
(infliximab-abda)

Remicade

Q5104

(PDF, 537 KB)

Ruxience
(rituximab-pvvr)

Rituxan

Q5119

(PDF, 811 KB)

Truxima
(rituximab-abbs)

Rituxan

Q5115

(PDF, 402 KB)

********* Embedded Contact Object*******